



Ekips Technologies Attracts \$2.9 Million

[Ekips Technologies](#) has announced \$2.9 million in funding from investors and the National Science Foundation Small Business Innovation Phase IIB program. The funds will be used to continue commercialization of its patented laser technologies used in industrial applications and medical devices. The company's flagship product, The Breathmeter, can easily and quickly diagnose and monitor asthmatic conditions in people of all ages, with the potential of diagnosing other chronic illnesses such as cancer.

Ekips Technologies, a company created around technology developed by University of Oklahoma engineering professor Patrick McCann, has closed a \$2.4 million round of equity financing and received a \$500,000 matching grant from the National Science Foundation through its Small Business Innovative Research program. Together, these funds will be used for product development, marketing efforts, and general business operations.

[Ekips's Breathmeter](#) measures biomarker molecules in exhaled breath. It contains a breath analysis sensor that uses a mid-infrared laser chip similar to the laser chips used in commercial DVD players. Breathmeter applications include asthma therapy monitoring, kidney function monitoring and cancer detection.

Future product offerings from Ekips could include laser-based sensors for measuring biomarker molecules in blood and urine samples. Successful development and commercialization of these laser-based chemical and biological sensors can create a new generation of point-of-care diagnostic tools that will help people live healthier lives. Ekips has several pending patents as well as exclusive licenses to five issued patents.